About Us
      Dr Dreams Health Blog bring you the latest health news, tips and advice to maintain a healthy body. Information on acne, losing and gaining weight, cancer, body building,exercise , latest health news and more.
    Recent Comments
      Great Sites To visit
      We Recommend
      Suggested Sites

RSS FeedSubscribe
A.M. Vitals: Roche Bids $5.7 Billion For Illumina
Home » Health » A.M. Vitals: Roche Bids $5.7 Billion For Illumina
By Dr Dreams | No CommentsLeave a Comment
Last updated: Wednesday, January 25, 2012

Hostile Bid For Illumina: Swiss drug maker Roche is making a $44.50 per-share hostile bid for Illumina, valuing the gene-sequencing company at $5.7 billion, the WSJ reports . Illumina has already rejected an offer of $40 per share, Roche says. The latest bid represents a premium of about 18% to Illumina’s $37.69 closing price Tuesday. Illumina said today it would review Roche’s proposal. PFCs and Vaccines: A study published in the Journal of the American Medical Association finds that increased exposure to chemicals known as PFCs is associated with a weaker immune response to the tetanus and diphtheria vaccines in children, NPR’s Shots blog reports . PFCs, some of which have been phased out by the EPA, are found in some food containers, non-stick coatings and stain-resistant fabrics, NPR reports. WellPoint Earnings: WellPoint’s fourth-quarter earnings fell 39% to $335.3

million, or 96 cents per share, due to investment losses and higher costs, the WSJ reports . Excluding special items, earnings fell to 99 cents. Analysts surveyed by Thomson Reuters had expected earnings of $1.12. Revenue rose 5.5% to $15.18 billion, less than the $15.41 billion expected by analysts. Grieving as Depression?: There’s controversy over the American Psychiatric Association’s proposed revision to the diagnosis of depression, which would encompass some people who are suffering bereavement after the loss of a loved one, the New York Times reports . A new report says counting some people who are grieving as depressed would lead to unnecessary treatment; other experts say that depression can indeed occur in the bereaved and that those people merit attention. Image: iStockphoto

See the rest here: 
A.M. Vitals: Roche Bids $5.7 Billion For Illumina

By Sean Duffy | No CommentsLeave a Comment
Last updated: Wednesday, January 25, 2012

Hostile Bid For Illumina: Swiss drug maker Roche is making a $44.50 per-share hostile bid for Illumina, valuing the gene-sequencing company at $5.7 billion, the WSJ reports . Illumina has already rejected an offer of $40 per share, Roche says. The latest bid represents a premium of about 18% to Illumina’s $37.69 closing price Tuesday. Illumina said today it would review Roche’s proposal. PFCs and Vaccines: A study published in the Journal of the American Medical Association finds that increased exposure to chemicals known as PFCs is associated with a weaker immune response to the tetanus and diphtheria vaccines in children, NPR’s Shots blog reports . PFCs, some of which have been phased out by the EPA, are found in some food containers, non-stick coatings and stain-resistant fabrics, NPR reports. WellPoint Earnings: WellPoint’s fourth-quarter earnings fell 39% to $335.3

million, or 96 cents per share, due to investment losses and higher costs, the WSJ reports . Excluding special items, earnings fell to 99 cents. Analysts surveyed by Thomson Reuters had expected earnings of $1.12. Revenue rose 5.5% to $15.18 billion, less than the $15.41 billion expected by analysts. Grieving as Depression?: There’s controversy over the American Psychiatric Association’s proposed revision to the diagnosis of depression, which would encompass some people who are suffering bereavement after the loss of a loved one, the New York Times reports . A new report says counting some people who are grieving as depressed would lead to unnecessary treatment; other experts say that depression can indeed occur in the bereaved and that those people merit attention. Image: iStockphoto

Read the original here: 
A.M. Vitals: Roche Bids $5.7 Billion For Illumina

By Martin Neumann | No CommentsLeave a Comment
Last updated: Wednesday, January 25, 2012

Hostile Bid For Illumina: Swiss drug maker Roche is making a $44.50 per-share hostile bid for Illumina, valuing the gene-sequencing company at $5.7 billion, the WSJ reports . Illumina has already rejected an offer of $40 per share, Roche says. The latest bid represents a premium of about 18% to Illumina’s $37.69 closing price Tuesday. Illumina said today it would review Roche’s proposal. PFCs and Vaccines: A study published in the Journal of the American Medical Association finds that increased exposure to chemicals known as PFCs is associated with a weaker immune response to the tetanus and diphtheria vaccines in children, NPR’s Shots blog reports . PFCs, some of which have been phased out by the EPA, are found in some food containers, non-stick coatings and stain-resistant fabrics, NPR reports. WellPoint Earnings: WellPoint’s fourth-quarter earnings fell 39% to $335.3 million,

or 96 cents per share, due to investment losses and higher costs, the WSJ reports . Excluding special items, earnings fell to 99 cents. Analysts surveyed by Thomson Reuters had expected earnings of $1.12. Revenue rose 5.5% to $15.18 billion, less than the $15.41 billion expected by analysts. Grieving as Depression?: There’s controversy over the American Psychiatric Association’s proposed revision to the diagnosis of depression, which would encompass some people who are suffering bereavement after the loss of a loved one, the New York Times reports . A new report says counting some people who are grieving as depressed would lead to unnecessary treatment; other experts say that depression can indeed occur in the bereaved and that those people merit attention. Image: iStockphoto

Go here to see the original: 
A.M. Vitals: Roche Bids $5.7 Billion For Illumina

By Sean Duffy | No CommentsLeave a Comment
Last updated: Wednesday, January 25, 2012

Hostile Bid For Illumina: Swiss drug maker Roche is making a $44.50 per-share hostile bid for Illumina, valuing the gene-sequencing company at $5.7 billion, the WSJ reports . Illumina has already rejected an offer of $40 per share, Roche says. The latest bid represents a premium of about 18% to Illumina’s $37.69 closing price Tuesday. Illumina said today it would review Roche’s proposal. PFCs and Vaccines: A study published in the Journal of the American Medical Association finds that increased exposure to chemicals known as PFCs is associated with a weaker immune response to the tetanus and diphtheria vaccines in children, NPR’s Shots blog reports . PFCs, some of which have been phased out by the EPA, are found in some food containers, non-stick coatings and stain-resistant fabrics, NPR reports. WellPoint Earnings: WellPoint’s fourth-quarter earnings fell 39% to $335.3

million, or 96 cents per share, due to investment losses and higher costs, the WSJ reports . Excluding special items, earnings fell to 99 cents. Analysts surveyed by Thomson Reuters had expected earnings of $1.12. Revenue rose 5.5% to $15.18 billion, less than the $15.41 billion expected by analysts. Grieving as Depression?: There’s controversy over the American Psychiatric Association’s proposed revision to the diagnosis of depression, which would encompass some people who are suffering bereavement after the loss of a loved one, the New York Times reports . A new report says counting some people who are grieving as depressed would lead to unnecessary treatment; other experts say that depression can indeed occur in the bereaved and that those people merit attention. Image: iStockphoto

Read the original here:
A.M. Vitals: Roche Bids $5.7 Billion For Illumina

By Martin Neumann | No CommentsLeave a Comment
Last updated: Wednesday, January 25, 2012

Hostile Bid For Illumina: Swiss drug maker Roche is making a $44.50 per-share hostile bid for Illumina, valuing the gene-sequencing company at $5.7 billion, the WSJ reports . Illumina has already rejected an offer of $40 per share, Roche says. The latest bid represents a premium of about 18% to Illumina’s $37.69 closing price Tuesday. Illumina said today it would review Roche’s proposal. PFCs and Vaccines: A study published in the Journal of the American Medical Association finds that increased exposure to chemicals known as PFCs is associated with a weaker immune response to the tetanus and diphtheria vaccines in children, NPR’s Shots blog reports . PFCs, some of which have been phased out by the EPA, are found in some food containers, non-stick coatings and stain-resistant fabrics, NPR reports. WellPoint Earnings: WellPoint’s fourth-quarter earnings fell 39% to

$335.3 million, or 96 cents per share, due to investment losses and higher costs, the WSJ reports . Excluding special items, earnings fell to 99 cents. Analysts surveyed by Thomson Reuters had expected earnings of $1.12. Revenue rose 5.5% to $15.18 billion, less than the $15.41 billion expected by analysts. Grieving as Depression?: There’s controversy over the American Psychiatric Association’s proposed revision to the diagnosis of depression, which would encompass some people who are suffering bereavement after the loss of a loved one, the New York Times reports . A new report says counting some people who are grieving as depressed would lead to unnecessary treatment; other experts say that depression can indeed occur in the bereaved and that those people merit attention. Image: iStockphoto

Read more:
A.M. Vitals: Roche Bids $5.7 Billion For Illumina

Dr.Dreams A Health,Medical & Wellness Blog